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SUMMARY
Laminopathies are genetic disorders associated with alterations in nuclear envelope proteins, 
known as lamins. The LMNA gene encodes lamins A and C, and LMNA mutations have been linked 
to diseases involving fat (type 2 familial partial lipodystrophy [FPLD2]), muscle (type 2 Emery–
Dreifuss muscular dystrophy [EDMD2], type 1B limb-girdle muscular dystrophy [LGMD1B], and 
dilated cardiomyopathy), nerves (type 2B1 Charcot–Marie–Tooth disease), and premature aging 
syndromes. Moreover, overlapping syndromes have been reported. This study aimed to determine 
the genetic basis of an overlapping syndrome in a patient with heart disease, myopathy, and features 
of lipodystrophy, combined with severe metabolic syndrome. We evaluated a 54-year-old woman 
with rheumatoid arthritis, chronic hypercortisolism (endogenous and exogenous), and a history 
of cured adrenal Cushing syndrome. The patient presented with a complex disorder, including 
metabolic syndrome associated with mild partial lipodystrophy (Köbberling-like); mild hypertrophic 
cardiomyopathy, with Wolff–Parkinson– White syndrome and atrial fibrillation; and limb-girdle 
inflammatory myopathy. Mutational analysis of the LMNA gene showed a heterozygous c.1634G>A 
(p.R545H) variant in exon 10 of LMNA. This variant has previously been independently associated 
with FPLD2, EDMD2, LGMD1B, and heart disease. We describe a new, LMNA-associated, complex 
overlapping syndrome in which fat, muscle, and cardiac disturbances are related to a p.R545H 
variant. Arch Endocrinol Metab. 2018;62(3):376-82
INTRODUCTION
Mutations in the LMNA gene (NM_170707.2) have been associated with a broad spectrum of diseases 
(1), including type 2 familial partial lipodystrophy 
(FPLD2), LMNA-related metabolic syndrome, 
type 2 Emery–Dreifuss muscular dystrophy (EDMD2), 
type 1B limb-girdle muscular dystrophy (LGMD1B), 
conduction-system diseases and dilated cardiomyopathy 
(DCM1A), and progeroid syndromes. FPLD2 begins 
in women during puberty, with a phenotype of fat loss 
in the limbs and buttocks, fat accumulation in the face 
and neck, well-defined musculature, phlebomegaly, 
insulin resistance, atherogenic dyslipidemia, and high 
cardiovascular risk (2).
The differential diagnosis includes Cushing’s 
syndrome and truncal obesity. Previous studies have 
described a LMNA-associated metabolic syndrome 
with a Köbberling-like fat distribution (3,4). EDMD2 
is characterized as a progressive skeletal muscle 
weakness associated with early joint contractures. 
LGMD1B causes muscular weakness in the spine and 
pelvic girdle (1).
Cardiac muscle laminopathies can present as 
nonspecific alterations in electrical conduction, or they 
can cause malignant arrhythmias and sudden death. 
Two of the most intriguing features of laminopathies 
are their clinical heterogeneity and the prevalence of 
overlapping syndromes. We investigated a female patient 
with a double Cushing syndrome (endogenous and 
exogenous), metabolic syndrome, cardiomyopathy, and 
limb-girdle muscular dystrophy. We aimed to determine 
whether this syndrome was related to a LMNA mutation.
CASE AND METHODS
This study was approved by the Ethics Review Panel 
of the Xunta de Galicia. The patient and her relatives 
provided informed consent for participation in the 
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Patient clinical history
The patient (Table 1) was a 45-year-old female 
diagnosed with rheumatoid arthritis at age 40 y and 
treated with corticosteroids from that point. She 
was referred to the Endocrinology Division due to 
high blood pressure, mixed dyslipidemia, and newly 
diagnosed diabetes (glycated hemoglobin: 9.6%; systolic 
blood pressure: 150 mmHg; diastolic blood pressure: 
90 mmHg; low-density lipoprotein cholesterol: 
5.2 mmol/L; high-density lipoprotein cholesterol: 
0.65 mmol/L; triglycerides: 3.42 mmol/L). The 
patient had had an android appearance since puberty, 
with mild lipoatrophy in the limbs and buttocks and fat 
accumulation in the abdomen and face (Figure 1). The 
patient reported that her deceased father had striking 
hypermuscular limbs, prominent abdominal fat, and 
diabetes. He had undergone a pacemaker implantation 
because of a third-degree atrioventricular block.
At age 46 y, the patient displayed poor glycemic 
control, and glucocorticoids were discontinued for 
several months, with no improvement. She was then 
diagnosed with adrenal Cushing’s syndrome, based on 
a 34-mm right adrenal adenoma (urinary free cortisol: 
1100 µg/ 24 h), which was histologically confirmed 
after a laparoscopic adrenalectomy. Additional 
hydrocortisone replacement was necessary, and the 
patient currently continues this treatment. After the 
adrenal tumor was resected, glycemic control, blood 
pressure, and lipid levels improved. She continued 
pharmacological treatment with antihypertensive drugs 
and metformin, but she was able to discontinue insulin.
Some months after the adrenalectomy, the patient 
was diagnosed with Wolff–Parkinson–White syndrome 
associated with atrial fibrillation, due to preexcitation, 
which was successfully ablated with radiofrequency. 
Transthoracic ultrasonography revealed a slightly 
hypertrophic non-dilated left ventricle, with preserved 
systolic function, type 1 diastolic dysfunction, and mild 
mitral regurgitation. No coronary lesions were detected 
with cardiac catheterization.
At age 50 y, the patient complained of muscular 
weakness without pain or contractures.
Table 1. Chronological evolution of clinical data
Age (years) 45 46 47 48 49-52
Event Adrenal
Diabetes. Start Cushing. Adrenal
antidiabetic Start statins surgery, Myopathy.
and and insulin; start Stop statins
antihypertensi intensive hydrocortiso at 49
ve drugs antihypertensi ne
ve therapy
BMI 30.5 31.7 30.8 36.5 25-26
BP (mmHg) 150/90 165/109 130/9 140/93 125/80
0
CPK (UI/L) - 176 88 157 378-2500
LDH (U/L) - - - 556-860
Glucose (mg/dL) 250 331 236 137 65-91
HbA1C (%) - 9.6 10.2 8.1 6-6.1
Triglycerides (mg/ dL) 164 122 146 254 202-214
HDL (mg/dL) - 37 41 30 40-40
LDL (mg/dL) - 161 126 - 63-139
Leptin (µg/L) - - 12.7 9.9 1-8.4
Insulin* (mUI/L) - 46.5 - - 43.9
UFC (Ug/24h) - 838 1014 - 36
Cortisol** (ug/dL) 23 30 27.4 2.2 1.6
ACTH - 13 9 - 60
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Figure 1. Photographs of the patient show body morphology due to a 
LMNA variant. (A) Before receiving a cure for Cushing’s syndrome (46 
years old). (B) Six years after receiving a cure for Cushing’s syndrome (54 
years old).
Creatine kinase levels ranged from 321 to 2525 
IU/L, and high levels persisted after discontinuation 
of statins. On physical examination, muscle weakness 
was evident, predominantly in the pelvic girdle. She 
was unable to get up from the ground and had marked 
difficulty in rising from a chair without hand support. 
Electromyoneurography revealed myopathy changes 
and spontaneous activity (fibrillation and positive 
waves) in proximal muscles, without polyneuropathy.
Body composition
Skinfolds (Table 2) were measured in triplicate on 
the dominant extremity with a Lange skinfold caliper 
(Cambridge Scientific Industries, MD, USA). Segmental 
body fat distribution was assessed with whole-body 
dual-energy X-ray absorptiometry, performed with a 
Lunar model DPX apparatus (GE Medical Systems, 
Milwaukee, WI, USA).
Molecular analyses
DNA was prepared from peripheral white blood cells 
following standard procedures (5). LMNA exons 1–12 
Table 2. Changes in body composition before and after Cushing cure evaluated by anthropometry and DXA
Active cushing Cured cushing Obese control* Non obese control*
Age 46 48.6
Weight (kg) 82.2 65.3
Height (cm) 161 161
BMI (kg/m2) 31.7 25.21 38.1 ± 6.5 26.6 ± 2.8
Tricipital skinfold (mm) 20 17 38.8 ± 10.0 29.4 ± 11.7
Bicipital skinfold (mm) 15 10 32.4 ± 11.6 21.5 ± 11.8
Suprailiac skinfold (mm) 42 15 52.2 ± 14.7 30.6 ± 14.4
Subescapular skinfold (mm) 35 18 44.2 ± 12.3 28.4 ± 16.4
Thigh skinfold (mm) 19 10 41.1 ± 14.5 22.7 ± 8.6
Calf skinfold (mm) 6 5 18.9 ± 14.2 11.2 ± 4.8
WHR 1.0 0.93 0.89 ± 0.08 0.88 ± 0.06
Total fat (kg) 37.5 20.06 43.8 ± 11.7 26.4 ± 7.7
Total fat (%) 46.1 30.6 48.2 ± 6.4 39.3 ± 7.0
Upper limbs fat (kg) 3.48 2.26 4.44 ± 1.1 3.1 ± 1.0
Upper limbs fat (%) 45.3 31.6 47.7 ± 5.7 42.1 ± 7.3
Lower limbs fat (kg) 9.69 6.16 12.4 ± 3.8 8.4 ± 2.2
Lower limbs fat (%) 40.8 30.5 44.6 ± 6.4 39.8 ± 6.4
Trunk fat (kg) 23.2 10.84 22.9 ± 5.1 14.0 ± 5.7
Trunk fat (%) 51.7 31.8 52.5 ± 7.6 40.8 ± 10.2
Visceral fat (g) ND 764 2012 ± 894 992 ± 693
Trunkal/Lower limbs fat ratio (kg) 2.39 1.75 1.61 1.66
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and the surrounding intronic sequences were amplified 
by PCR. Primers and conditions have been previously 
described (6).
Histological muscle studies
Deltoid muscle biopsy samples were snap frozen in liquid 
nitrogen, and cryostat sections were processed and stained 
to exclude dystrophies and other pathological conditions 
(e.g., mitochondrial myopathies, metabolic diseases) as 
follows: PAS, modified Gomori trichrome, Oil Red O, 
enzyme histochemistry (muscle phosphorylase, muscle 
phosphofructokinase, lactate dehydrogenase, AMP 
deaminase, cytochrome-C oxidase, SDH, and NADH), 
and immunohistochemistry (beta-spectrin to check 
preservation of the plasma membrane; slow, fast, and 
fetal myosin; utrophin; alpha, beta, gamma, and delta 
sarcoglycan; dystrophin fractions: N- terminal, C-terminal, 
and rod domain; NOS; alpha and beta dystroglycan; 
dysferlin, caveolin-3, collagen type VI, laminin alpha2 
chain of merosin (laminin-2), telethonin, myotilin, 
desmin, calpain-3, MHC class I antigen, and inflammatory 
markers (CD68/KP1, CD3 and CD20 for histiocytes and 
lymphocytes). The only commercial antibodies available 
for Lamin A/C are not helpful for diagnostic purposes 
(here it was used as a positive control for emerin antibody).
Immunostains were performed after antigen retrieval 
using a standard avidin–biotin immunoperoxidase 
detection technique (EnVision Systems, Dako, Glostrup, 
Denmark).
RESULTS
We identified a heterozygous c.1634G>A (p.R545H) 
variant of LMNA, located in exon 10. This variant 
had not been probed for pathogenicity with in silico 
approaches (PolyPhen and SIFT).
Its allelic frequency was 0.00019 (1000 Genomes 
Project). Of the patient’s relatives whom we studied 
(mother, sisters, offspring), none carried this variant. 
Histological findings of muscle samples were consistent 
with acute and chronic, nonspecific, inflammatory 
myopathy (Figure 2).
Figure 2. (1) Snap frozen cryostat sections of deltoid muscle showing endomisial inflammatory infiltrates composed mainly of hystiocytes (asterisks) 
(Hematoxylin and eosin, 400x). (2) MHC class I antigen is upregulated in all fibers, with immunolabeling at plasma membrane (arrow) and sarcoplasm 
(asterisk). See also “pseudovacuoles” secondary to “ice crystals” snap frozen artifact (arrow head) (Immunoperoxidase reaction, diaminobenzidine brown 
staining chromogen, 400x). (3a) Immunostaining of CD68 (KP1) antibody remark histiocityc inflammatory component between myofibers, with (3b) a 
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autoimmune background. Chronic hypercortisolism 
causes a characteristic fat distribution, in particular, 
excess abdominal fat (19); however, no particular 
changes in limb fat have been reported (20). Strikingly, 
in this patient, once hypercortisolism was cured, 
an abnormal fat distribution became more evident, 
although it was not as severe as observed in classical 
Dunnigan disease. This change in fat distribution was 
particularly intriguing because it highlighted important 
differences among LMNA mutations that cause FPLD 
(13). The R545H variant, previously associated with 
FPLD (7), caused severe metabolic syndrome with 
android fat distribution in this patient.
The patient was initially diagnosed with 
polymyositis, based on girdle weakness, high creatine 
kinase, and muscle lymphocyte infiltration. Because 
of her autoimmune background, this diagnosis was 
probably the most parsimonious. However, the 
R545H variant has been associated with LGMD1B 
(9), which clinically overlaps with polymyositis. Other 
LMNA mutations that cause muscular and/or cardiac 
laminopathies have been related to inflammatory 
changes in muscle specimen biopsies. For example, in 
biopsies from patients with infantile- onset LMNA-
associated myopathy, Komaki and cols. (21) reported 
mononuclear cell infiltrations that were positive for 
lymphocyte markers CD4, CD8, or CD20, active 
necrosis, and regeneration. Additionally, they observed 
elevated sarcolemmal HLA staining in many fibers. 
Similarly, HLA class I antigens were upregulated in our 
samples and in samples described previously in a study 
on LGMD1B (15,16). It cannot be ruled out that 
chronic hypercortisolism had influenced the myopathy. 
However, there are some clues to differences between 
the corticoid-myopathy case and the case described 
here.
In the first case, serum values of muscle 
enzymes are typically normal or slightly elevated, 
electromyoneurography is usually normal, and there are 
no inflammatory infiltrates or necrosis on muscle biopsy 
samples (22). Although unusual, polymyositis has been 
associated with cardiac involvement, manifested as 
rhythm disturbances, conduction defects, and heart 
failure (23). Similarly, laminopathies, like FPLD2 or 
LGMD1B (9,14), and particularly the R545H variant, 
have also been related to heart disease (10). Patients 
with cardiac compromise related to LMNA typically 
show initial signs of nonspecific rhythm disturbances 
after age 30 y (24), and they frequently need a 
DISCUSSION
We investigated an unusual case of laminopathy and 
found that it was due to a p.R545H LMNA variant 
that overlapped with chronic hypercortisolism. Thus, 
after chronic hypercortisolism had been diagnosed 
and cured, the patient exhibited atypical partial 
lipodystrophy, idiopathic inflammatory myopathy, 
and cardiomyopathy with conduction disturbances. 
Although this variant has not been shown to be 
pathogenic with in silico approaches, it has been 
associated with FPLD2 (7), EDMD2 (8), LGMD1B 
(9), and heart disease (10).
In FPLD2, more than 80% of cases are due to 
missense mutations in exon 8; however, atypical 
phenotypes have been related to mutations in other 
exons (11). Moreover, several patients with mutations 
outside the immunoglobulin-like fold of lamin A have 
lacked the typical FPLD2 phenotype but experienced 
insulin resistance (4). In addition, some cases of FPLD2 
have been associated with heart conduction disorders, 
valvulopathies, and cardiomyopathy (12-14). Other 
authors have reported LMNA-associated complex 
phenotypes, including heart failure and limb-girdle 
muscular dystrophy, due to a Ser334del variant (15,16); 
muscular dystrophy, lipodystrophy, and cardiac rhythm 
disturbances related to a R527P variant (17); or FPLD, 
early heart failure, first-degree atrioventricular block, 
and late proximal muscle weakness due to a R28W 
variant (12).
Exon 10 of LMNA corresponds to the C-terminal 
domain, common to both lamins A and C, which 
forms an immunoglobulin-like, three-dimensional 
structure (1). The conformation of this domain is well 
defined for residues 430–545 (18). Arginine 545 is at 
the external surface of the structure. Mutations in the 
Ig-fold can affect either head-to-tail polymerization, 
which destabilizes the three-dimensional structure of 
the C-terminal domain, or lamin A/C interactions with 
other proteins (1). At least 13 missense mutations at 
the C-terminal domain are related to EDMD2 (18), 
including the nearby R541H. Although the R545 
residue has not been specifically studied, it does not 
seem to influence the stability of the 3D structure. 
However, the exchange of arginine (positive polar) for 
histidine (neutral polar) could alter interactions with 
other proteins at the nuclear lamina.
This study was particularly challenging because 
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permanent pacemaker. Later, cardiac compromise may 
be further complicated with cardiomyopathy (25). Our 
patient was diagnosed with Wolff–Parkinson–White 
syndrome, atrial fibrillation, mitral regurgitation, and 
mild hypertrophic cardiomyopathy. Taken together, the 
diagnoses of severe metabolic syndrome, girdle weakness 
appearing in the fourth decade, and heart involvement 
in a patient that carried the R545H variant in LMNA 
resembled a complex laminopathic disorder. However, 
the presence of chronic hypercortisolism represented a 
confounding factor, and rheumatoid arthritis prevented 
us from definitely ruling out a random association of 
different unrelated autoimmune entities.
In summary, this case emphasizes the need for 
actively searching for LMNA mutations in patients with 
clinical features compatible with partial lipodystrophy, 
cardiac conduction abnormalities, cardiomyopathy, 
and/or certain types of myopathy. A correct diagnosis 
can facilitate early interventions to prevent the 
consequences of these pathologies, which can be lethal.
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